Eupraxia Pharmaceuticals Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 49

Employees

  • Stock Symbol
  • EPRX

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $6.13
  • (As of Thursday Closing)

Eupraxia Pharmaceuticals General Information

Description

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.

Contact Information

Formerly Known As
Plaza Capital Partners
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 2198 Yukon Street
  • Vancouver, British Columbia V5Y 3P1
  • Canada
+1 (250)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
TSE
Corporate Office
  • 2198 Yukon Street
  • Vancouver, British Columbia V5Y 3P1
  • Canada
+1 (250)

Eupraxia Pharmaceuticals Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eupraxia Pharmaceuticals Stock Performance

As of 19-Nov-2026, Eupraxia Pharmaceuticals’s stock price is $6.13. Its current market cap is $412M with 67.3M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.13 $6.19 $5.61 - $9.29 $412M 67.3M 91.2K -$1.07

Eupraxia Pharmaceuticals Financials Summary

As of 30-Sep-2026, Eupraxia Pharmaceuticals has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 500,717 322,011 102,423 95,691
Revenue 0 0 0 0
EBITDA (62,943) (39,761) (26,127) (28,467)
Net Income (59,093) (38,576) (25,503) (28,221)
Total Assets 134,563 86,150 34,942 20,266
Total Debt 3,422 154 72 10,452
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Eupraxia Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Eupraxia Pharmaceuticals‘s full profile, request access.

Request a free trial

Eupraxia Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered,
Drug Discovery
Vancouver, Canada
49 As of 2025

Newark, CA
 

Edmonton, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eupraxia Pharmaceuticals Competitors (47)

One of Eupraxia Pharmaceuticals’s 47 competitors is Protagonist Therapeutics, a Formerly VC-backed company based in Newark, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Protagonist Therapeutics Formerly VC-backed Newark, CA
Aurinia Pharmaceuticals Corporation Edmonton, Canada
Zymeworks Formerly VC-backed Vancouver, Canada
Aclaris Therapeutics Formerly VC-backed Wayne, PA
Arbutus Biopharma Corporation Warminster, PA
You’re viewing 5 of 47 competitors. Get the full list »

Eupraxia Pharmaceuticals Patents

Eupraxia Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024310803-A1 Long-acting intra-articular dosage forms containing fluticasone propionate and use thereof Pending 26-Jun-2023
EP-4731193-A1 Long-acting intra-articular dosage forms containing fluticasone propionate and use thereof Pending 26-Jun-2023
US-20240424000-A1 Long-acting intra-articular dosage forms containing fluticasone propionate and use thereof Pending 26-Jun-2023
WO-2025006497-A1 Long-acting intra-articular dosage forms containing fluticasone propionate and use thereof Inactive 26-Jun-2023
AU-2023356957-A1 Use of long-acting fluticasone propionate injectable suspensions for treating and preventing inflammations of the gastrointestinal tract Pending 04-Oct-2022 A61K9/0019
To view Eupraxia Pharmaceuticals’s complete patent history, request access »

Eupraxia Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eupraxia Pharmaceuticals Acquisitions (2)

Eupraxia Pharmaceuticals’s most recent deal was a Merger/Acquisition with EpiPharma Therapeutics. The deal was made on 01-Jan-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
EpiPharma Therapeutics 01-Jan-2023 Merger/Acquisition Drug Discovery
AMDM Holdings 31-Jan-2021 Merger/Acquisition Other Commercial Products
To view Eupraxia Pharmaceuticals’s complete acquisitions history, request access »

Eupraxia Pharmaceuticals ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Commercial Services

Industry

Rank

Percentile

Business Support Services

Subindustry

Rank

Percentile

To view Eupraxia Pharmaceuticals’s complete esg history, request access »

Eupraxia Pharmaceuticals FAQs

  • When was Eupraxia Pharmaceuticals founded?

    Eupraxia Pharmaceuticals was founded in 2011.

  • Where is Eupraxia Pharmaceuticals headquartered?

    Eupraxia Pharmaceuticals is headquartered in Vancouver, Canada.

  • What is the size of Eupraxia Pharmaceuticals?

    Eupraxia Pharmaceuticals has 49 total employees.

  • What industry is Eupraxia Pharmaceuticals in?

    Eupraxia Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Eupraxia Pharmaceuticals a private or public company?

    Eupraxia Pharmaceuticals is a Public company.

  • What is Eupraxia Pharmaceuticals’s stock symbol?

    The ticker symbol for Eupraxia Pharmaceuticals is EPRX.

  • What is the current stock price of Eupraxia Pharmaceuticals?

    As of 19-Nov-2026 the stock price of Eupraxia Pharmaceuticals is $6.13.

  • What is the current market cap of Eupraxia Pharmaceuticals?

    The current market capitalization of Eupraxia Pharmaceuticals is $412M.

  • Who are Eupraxia Pharmaceuticals’s competitors?

    Protagonist Therapeutics, Aurinia Pharmaceuticals, Zymeworks, Aclaris Therapeutics, and Arbutus Biopharma are some of the 47 competitors of Eupraxia Pharmaceuticals.

  • What is Eupraxia Pharmaceuticals’s annual earnings per share (EPS)?

    Eupraxia Pharmaceuticals’s EPS for 12 months was -$1.07.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process